

Literatur zu „Forschung zu Misteleextrakten bei Krebs – Einleitung „
Literature on „Mistletoe in Cancer Treatment – Introduction to Research“

- [1] Auerbach, L., V. Dostal, I. Václavik-Fleck, E. Kubista, A. Rosenberger, S. Rieger, W. Tröger and J. M. Schierholz, *Signifikant höherer Anteil aktivierter NK-Zellen durch additive Misteltherapie bei chemotherapierten Mamma-Ca-Patientinnen in einer prospektiven randomisierten doppelblinden Studie.* In *Fortschritte in der Misteltherapie. Aktueller Stand der Forschung und klinischen Anwendung.* (Ed. R. Scheer, R. Bauer, H. Becker, V. Fintelmann, F. H. Kemper and H. Schilcher) pp. 543-554, KCV Verlag, Essen 2005.
- [2] Büssing, A. and (ed.), Mistletoe. The Genus *Viscum*, pp. 1-265, Hardwood Academic Publishers, Amsterdam 2000.
- [3] Büssing, A., T. Azhari, K. Ostendorp, A. Lehnert and K. Schweizer, *Viscum album L. extracts reduce sister chromatid exchanges in cultured peripheral blood mononuclear cells.* Eur J Cancer 30A, 1836-1841 (1994).
- [4] Büssing, A., H. Jungmann, K. Suzart and K. Schweizer, *Suppression of sister chromatid exchange-including DNA lesions in cultured peripheral blood mononuclear cells by Viscum album L.* J Exp Clin Cancer Res 15, 107-114 (1996).
- [5] Büssing, A., A. Regnery and K. Schweizer, *Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: sister chromatid exchanges and activation/proliferation marker expression.* Cancer Lett 199-205 (1995).
- [6] Büssing, A., G. Schaller and U. Pfüller, *Generation of reactive oxygen intermediates (ROI) by the thionins from Viscum album L.* Anticancer Res 18, 4291-4296 (1998).
- [7] Büssing, A., K. Suzart, J. Bergmann, U. Pfüller, M. Schietzel and K. Schweizer, *Induction of apoptosis in human lymphocytes treated with Viscum album L. is mediated by the mistletoe lectins.* Cancer Lett 59-72 (1996).
- [8] Büssing, A., W. Vervecken, M. Wagner, B. Wagner, U. Pfüller and M. Schietzel, *Expression of mitochondrial Apo2.7 molecules and Caspase-3 activation in human lymphocytes treated with the ribosome-inhibiting mistletoe lectins and the cell membrane permeabilizing viscotoxins.* Cytometry 37, 133-139 (1999).
- [9a] Fasching, P.A., F. Thiel, K. Nicolaisen-Murmann, C. Rauh, J. Engel, M.P. Lux, et al. *Association of complementary methods with quality of life and life satisfaction in patients with gynecologic and breast malignancies.* Support Care Cancer 55 (11), 1277-84 (2007).
- [9b] Franz, H., P. Ziska and A. Kindt, *Isolation and properties of three lectins from mistletoe (Viscum album L.).* Biochem J 195, 481-484 (1981).
- [10] Janssen, O., A. Scheffler and D. Kabelitz, *In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis).* Arzneim -Forsch /Drug Res 43(II), 1221-1227 (1993).

- [11] Kienle, G. S., F. Berrino, A. Büsing, E. Portalupi, S. Rosenzweig and H. Kiene, *Mistletoe in cancer - a systematic review on controlled clinical trials*. Eur J Med Res 8, 109-119 (2003).
- [12] Kienle, G. S. and H. Kiene, Die Mistel in der Onkologie - Fakten und konzeptionelle Grundlagen, Schattauer Verlag, Stuttgart, New York 2003.
- [13] Kienle, G. S., Kiene, H. and Albonico, H. U. Health Technology Assessment Bericht Anthroposophische Medizin. Erstellt im Rahmen des Programm Evaluation Komplementärmedizin (PEK) des Schweizer Bundesamtes für Sozialversicherung. 2005.
- [14] Kienle, G. S., H. Kiene and H. U. Albonico, Anthroposophische Medizin in der klinischen Forschung. Wirksamkeit, Nutzen, Wirtschaftlichkeit, Sicherheit. Schattauer Verlag, Stuttgart, New York 2006.
Kienle, G. S., H. Kiene and H. U. Albonico, Anthroposophic Medicine: Effectiveness, Utility, Costs, Safety, Schattauer Verlag, Stuttgart, New York 2006.
- [15a] Klett, C. Y. and F. A. Anderer, *Activation of natural killer cell cytotoxicity of human blood monocytes by a low molecular weight component from Viscum album extract*. Arzneim -Forsch /Drug Res 39 (II), 1-20 (1989).
- [15b] Kovacs, E., T. Hajto and K. Hostanska, *Improvement of DNA repair in lymphocytes of breast cancer patients treated with Viscum album extract (Iscador)*. Eur J Cancer 27, 1672-1676 (1991).
- [15c] Längler A., C. Spix, G. Seifert, S. Gottschling, N. Graf, P. Kaatsch, *Complementary and alternative treatment methods in children with cancer: A population-based retrospective survey on the prevalence of use in Germany*. Eur J Cancer 44:2233-2240 (2008)
- [16] Molassiotis, A., P. Fernandez-Ortega, D. Pud, G. Ozden, J. A. Scott, V. Panteli and et al., *Use of complementary and alternative medicine in cancer patients: a European survey*. Ann Oncol Advance Access published online on February 2, doi:10.1093/annonc/mdi110 (2005).
- [17] Münstedt K., R. von Georgi. *Unkonventionelle Krebstherapien – Vergleich von Einstellungen und Kenntnissen bei Ärzten in Deutschland und Griechenland*. Forsch Komplementärmed Klass Naturheilkd 12:254-260 (2005)
- [18] Mueller, E. A. and F. A. Anderer, *A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon gamma inducer*. Cancer Immunol Immunother 32, 221-227 (1990).
- [19] Petru, E., P. Schmied and C. Petru, *[Complementary Measures Used by Patients With Gynecologic Cancers Undergoing Cytotoxic or Hormonal Chemotherapy]*. Geburtshilfe Frauenheilkd 61, 75-78 (2001).
- [20] Rostock, M. and R. Huber, *Randomized and double-blind studies - demands and reality as demonstrated by two examples of mistletoe research*. Forsch Komplementärmed 11, 18-22 (2004).

- [21] Schöffski, P., S. Riggert, P. Fumoleau, M. Campone, O. Bolte, S. Marreaud, D. Lacombe and et al., *Phase I trial on intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group*. Ann Oncol 15, 1816-1824 (2004).
- [22] Steiner, R., Geisteswissenschaft und Medizin. (1920), Rudolf Steiner Verlag, Dornach 1985.
- [23] Urech, K., J. M. Scher, K. Hostanska and H. Becker, *Apoptosis inducing activity of viscin, a lipophilic extract from Viscum album L.* J Pharm Pharmacol 57, 101-109 (2005).
- [24] Weis, J., H. H. Bartsch, F. Hennies, M. Rietschel, M. Heim, G. Adam, U. Gärtner and A. Ammon, *Complementary medicine in cancer patients: demand, patients' attitudes and psychological beliefs*. Onkologie 21, 144-149 (1998).
- [25] Winterfeld, K. and A. B. Bijnen, *Viscotoxin, ein neuer Inhaltsstoff der Mistel (Viscum album L.)*. Liebigs Ann Chem 561, 107-115 (1948).
- [26] Winterfeld, K. and A. Kronenthaler, *Zur Chemie des blutdrucksenkenden Bestandteils der Mistel. (Viscum album)*. Arch Pharm 280, 103-115 (1942).